BBOT
BridgeBio Oncology Therapeutics, Inc.11.85
-0.15-1.25%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
947.87MP/E (TTM)
-Basic EPS (TTM)
-1.45Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
BridgeBio Oncology Therapeutics, Inc. (BBOT) completed its business combination with Helix Acquisition Corp. II on August 11, 2025, becoming a publicly traded company listed on Nasdaq under ticker BBOT. The transaction included a $261 million PIPE financing led by Cormorant Asset Management, resulting in approximately $490 million in cash, cash equivalents, and marketable securities. BBOT focuses on developing novel small-molecule therapeutics targeting RAS and PI3K malignancies, with three clinical-stage candidates: BBO-8520 (KRAS G12C inhibitor in Phase 1), BBO-10203 (RAS-PI3K interaction inhibitor in Phase 1), and BBO-11818 (pan-KRAS inhibitor in Phase 1). The company raised $366.8 million from the deal, including PIPE proceeds and unredeemed SPAC trust funds, to advance its pipeline. Leadership includes CEO Eli Wallace, PhD, and Chairman Frank McCormick, PhD. The unaudited pro forma condensed combined financial information shows a balance sheet with $509.8 million in assets and $481.3 million in stockholders' equity as of June 30, 2025, and net losses of $54.1 million for the six months ended June 30, 2025, and $78.7 million for the year ended December 31, 2024.
BridgeBio Oncology Therapeutics, Inc. (BBOT) completed its business combination with Helix Acquisition Corp. II on August 11, 2025, becoming a publicly traded company listed on Nasdaq under ticker BBOT. The transaction included a $261 million PIPE financing led by Cormorant Asset Management, resulting in approximately $490 million in cash, cash equivalents, and marketable securities. BBOT focuses on developing novel small-molecule therapeutics targeting RAS and PI3K malignancies, with three clinical-stage candidates: BBO-8520 (KRAS G12C inhibitor in Phase 1), BBO-10203 (RAS-PI3K interaction inhibitor in Phase 1), and BBO-11818 (pan-KRAS inhibitor in Phase 1). The company raised $366.8 million from the deal, including PIPE proceeds and unredeemed SPAC trust funds, to advance its pipeline. Leadership includes CEO Eli Wallace, PhD, and Chairman Frank McCormick, PhD. The unaudited pro forma condensed combined financial information shows a balance sheet with $509.8 million in assets and $481.3 million in stockholders' equity as of June 30, 2025, and net losses of $54.1 million for the six months ended June 30, 2025, and $78.7 million for the year ended December 31, 2024.
8-K
Low redemptions boost biotech SPAC
Helix Acquisition Corp. II retained approximately $120 million in its trust account after redemptions, exceeding 60% of the funds and marking the second-lowest redemption rate for a biotech de-SPAC since 2022. Combined with $261 million from a PIPE led by Cormorant Asset Management and top investors, the deal delivers $382 million in gross proceeds to fuel BridgeBio Oncology Therapeutics' RAS and PI3Kα cancer pipeline. Closing awaits standard conditions. Low redemptions signal strong backing.
8-K
Helix approves BBOT merger
Helix Acquisition Corp. II shareholders overwhelmingly approved key proposals at their August 4, 2025, extraordinary general meeting, greenlighting a business combination with TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) via merger, alongside domestication to Delaware and issuance of PubCo common stock. The vote, with 82.55% quorum and strong majorities for all items including director elections and incentive plans, paves the way for renaming to BridgeBio Oncology Therapeutics, Inc. Closing hinges on regulatory nods. Yet risks loom from redemptions and approvals.
BBIO
BridgeBio Pharma, Inc.
75.69+1.18
BDTX
Black Diamond Therapeutics, Inc
2.62-0.03
BOLD
Boundless Bio, Inc.
1.14+0.00
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CRDF
Cardiff Oncology, Inc.
2.40-0.01
ELTX
Elicio Therapeutics, Inc.
8.15-0.37
KURA
Kura Oncology, Inc.
10.63+0.07
NUVB
Nuvation Bio Inc.
8.66+0.15
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
TNGX
Tango Therapeutics, Inc.
8.96-0.16